Inhaled IPF Therapy LTI-03 Well-Tolerated in Healthy Volunteers

Inhaled IPF Therapy LTI-03 Well-Tolerated in Healthy Volunteers

Lung Therapeutics’ LTI-03, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF), was safe and well-tolerated in healthy volunteers, with no reports of serious adverse events (side effects) or discontinuations, according to a Phase 1a trial. “We are pleased that LTI-03 has passed this important safety milestone as…

IPF Didn’t Change My Identity

The word “identity,” which refers to a person’s “distinguishing character or personality,” according to Merriam-Webster, may sound simple to understand, but it’s actually often confused with other terms. Before you read any further, take a moment to think about your own identity. When you have a description in mind, please…

TGen Will Use Big Memory Technology to Accelerate IPF Research

The Translational Genomics Research Institute (TGen) will use a big-memory technology, called MemVerge Memory Machine Big Memory virtualization software, to accelerate research on the cellular mechanisms underlying idiopathic pulmonary fibrosis (IPF). “MemVerge Memory Machine has quickly resulted in research value for TGen,” Jonathan Jiang, chief operating officer of…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums